- Home
- CVM
as of 08-17-2026 2:43pm EST
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | VIENNA |
| Market Cap: | 30.1M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 212.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | -1129.41 |
| 52 Week Low/High: | $0.89 - $13.48 | Next Earning Date: | 05-13-2026 |
| Revenue: | $264,033 | Revenue Growth: | 65.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.88 | Index: | N/A |
| Free Cash Flow: | -17157846.0 | FCF Growth: | N/A |
Compare CVM vs Leading Stocks
See how CVM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CVM Cel-Sci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.